Nocion is developing a new class of small molecules, nocions™, designed to selectively silence activated sensory neurons that drive disease in conditions such as cough, pain, itch, and neurogenic inflammation. Our platform is built on a simple but powerful insight: many chronic conditions are driven by hyperexcitable sensory neurons that continue to fire long after the original triggers have passed. By directly targeting how these neurons signal to the central nervous system rather than blocking upstream triggers or broadly suppressing the nervous system, Nocion aims to deliver precise, durable symptom control with disease modification, while maintaining a favorable safety profile.
Sensory neurons, or nociceptors, detect environmental and inflammatory stimuli through a variety of receptors and ion channels. When activated, these neurons generate action potentials that signal to the central nervous system and are perceived as cough, pain, or itch. Many existing approaches to treating these conditions attempt to:
The permanent positive charge of nocions is central to their behavior: